G. John Mohr Joins Immune Pharmaceuticals as Senior Vice President of Business Development
New role strengthens Immune's ability to advance portfolio through strategic partnering
Dec 7, 2015
NEW YORK, Dec. 7, 2015 /PRNewswire/ -- Immune Pharmaceuticals Inc. (NASDAQ:IMNP) ("Immune" or the "Company") a clinical-stage company developing novel therapies for the treatment of immuno-inflammatory diseases and cancer today announced that it has appointed G. John Mohr as senior vice president of business development and a member of the Immune executive committee. In this role, John Mohr will be responsible for overseeing alliance and business development activities for the Company.
John Mohr has served in the pharmaceutical business for over twenty years in multiple functions including business development, strategic planning and marketing. Prior to joining Immune, he was managing director at the consulting firm BioAsset Advisors advising public and private companies on strategic partnering and licensing activities.
"We are pleased to have John join us to lead our business development and partnering activities," said Dr. Daniel Teper, CEO of Immune. "As a senior-level executive John has been involved in many significant transactions and brings valuable deal execution experience to our team. John is well acquainted with our Company's lead program, bertilimumab, and served as an advisor to Immune when at the time we acquired the license. John shares our vision for bertilimumab and will be leading our efforts to maximize strategic transactions for our entire portfolio."
John Mohr previously served as senior vice president with CV Therapeutics, a publicly traded drug company focused on innovative cardiovascular therapeutics, and he lead several major global transactions with Menarini and Astellas. In addition, he was instrumental in the $1.4 billion sale of the company to Gilead in 2009. Prior to that, he was the chief operating officer for Topigen Pharmaceuticals, a clinical stage company developing innovative therapeutics in the respiratory field. He was senior vice president with Atherogenics and President of Fournier Pharma US, where he delivered billion dollar deals with AstraZeneca and Abbott. John is a graduate of Drexel University in Finance and Accounting, a CPA and certified licensing executive.
"This is a pivotal time to join the Company," said John Mohr. "In addition to the exciting opportunity with bertilimumab progressing in the clinic, Immune has several other valuable programs to offer for partnering. I look forward to adding value to Immune and working with the team."
About Immune Pharmaceuticals:
Immune Pharmaceuticals (NASDAQ: IMNP) applies a personalized approach to treating and developing novel, highly-targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer. Immune's lead product candidate, bertilimumab, is in phase II clinical development for moderate-to-severe ulcerative colitis as well as for bullous pemphigoid, an orphan auto-immune dermatological condition. Other indications being considered for development include atopic dermatitis, Crohn's disease, severe asthma and NASH (an inflammatory liver disease). Immune recently expanded its portfolio in immuno-dermatology with topical nano-formulated cyclosporin A for the treatment of psoriasis and atopic dermatitis. Immune's oncology pipeline includes, bi-specific antibodies nanotherapeutics, including NanomAbs®, and several mid-to late stage small molecules .Immune's non-core pipeline includes AmiKet™, a late clinical stage drug candidate for the treatment of neuropathic pain. For more information, visit Immune's website at www.immunepharmaceuticals.com.
This news release and any oral statements made with respect to the information contained in this news release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You are urged to consider statements that include the words "may," "will," "would," "could," "should," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal" or the negative of those words or other comparable words to be uncertain and forward-looking. Such forward-looking statements include statements that express plans, anticipation, intent, contingency, goals, targets, future development and are otherwise not statements of historical fact. These statements are based on our current expectations and are subject to risks and uncertainties that could cause actual results or developments to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Factors that may cause actual results or developments to differ materially include, but not limited to: the risks associated with the adequacy of our existing cash resources and our ability to continue as a going concern; the risks associated with our ability to continue to meet our obligations under our existing debt agreements; the risk that clinical trials for bertilimumab or AmiKet™ will not be successful; the risk that bertilimumab, AmiKet or compounds arising from our NanomAbs program will not receive regulatory approval or achieve significant commercial success; the risk that we will not be able to find a partner to help conduct the Phase III trials for AmiKet on attractive terms, on a timely basis or at all; the risk that our other product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later-stage clinical trials; the risk that we will not obtain approval to market any of our product candidates; the risks associated with dependence upon key personnel; the risks associated with reliance on collaborative partners and others for further clinical trials, development, manufacturing and commercialization of our product candidates; the cost, delays and uncertainties associated with our scientific research, product development, clinical trials and regulatory approval process; our history of operating losses since our inception; the highly competitive nature of our business; risks associated with litigation; and risks associated with our ability to protect our intellectual property. These factors and other material risks are more fully discussed in our periodic reports, including our reports on Forms 8-K, 10-Q and 10-K and other filings with the U.S. Securities and Exchange Commission. You are urged to carefully review and consider the disclosures found in our filings, which are available at www.sec.gov or at www.immunepharmaceuticals.com. You are cautioned not to place undue reliance on any forward-looking statements, any of which could turn out to be wrong due to inaccurate assumptions, unknown risks or uncertainties or other risk factors. We expressly disclaim any obligation to publicly update any forward looking statements contained herein, whether as a result of new information, future events or otherwise, except as required by law.
SOURCE Immune Pharmaceuticals, Inc.
For further information: Christine J. Petraglia, Director, Investor Relations, IMMUNE Pharmaceuticals, Inc., 646.440.9332, email@example.com